Pharma’s interest in using big data to demonstrate the value of its medicines and efforts to expand services to patients beyond the pill are resulting in more deals between biopharma and non-traditional partners like digital health firms, data management companies and other service providers.
The growing interest in these kinds of alternative deals, generally partnerships and alliances instead of outright M&A, was evident in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?